Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...

Shares of Hims & Hers Health ($HIMS) rallied in pre-market hours on Tuesday after management said it’s in discussions with ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Novo Nordisk A/S (NYSE:NVO) is one of the best long term low volatility stocks to buy right now. J.P. Morgan analyst Richard ...

Danish pharma major Novo Nordisk today confirmed that it submitted an unsolicited proposal to acquire Metsera, aiming to ...

Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy. The Danish ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of ...

Pharma major CEO Mike Doustdar, on Friday, 31 October 2025, said that the company has notified its employees who have been ...

After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is ...

China-headquartered Innovent Bio has announced that the fourth Phase III trial DREAMS-3 of mazdutide, a glucagon-like peptide ...

The Danish drugmaker plans to cut 9,000 jobs or 11% of its workforce, which would save it 8 billion Danish krone ($1.25 ...

Get the daily news here. Read the essential Danish news and topics of today - in English. Politiken Edition is your window to ...